Pancreatic Cancer Research

ResearcherKoç UniversityActive in the last 2 years

Mert Erkan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2753-0234; OpenAlex author ID A5015386151, A5045175021, A5054322982, A5105233970. Sources: OpenAlex.

Their work

Papers
46 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
135
Papers, trials and grants by year

2011: 5 papers · 2012: 4 papers · 2013: 2 papers · 2014: 3 papers · 2015: 11 papers · 2016: 2 papers · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 3 papers · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 5 papers

Papers 46

  1. Heterogeneity in the management of patients with locally advanced pancreatic cancer: current surgeons' perspective and lessons for the future. Co-author DOI 10.1007/s13304-026-02651-5↗
  2. R0 Resection improves survival after multivisceral resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2026.117352↗
  3. HSP47 is a potential dual cell target and prognostic factor in pancreatic cancer. Co-author DOI 10.1038/s41388-026-03865-y↗
  4. βIII-tubulin can act as a brake on extrinsic apoptosis in pancreatic cancer. Co-author DOI 10.1038/s41419-026-08657-6↗
  5. Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarc… Co-author DOI 10.1038/s41591-026-04234-8↗
  6. MYH knockdown in pancreatic cancer cells creates an exploitable DNA repair vulnerability. Co-author DOI 10.1016/j.neo.2025.101138↗
  7. Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarc… Co-author DOI 10.1038/s41591-024-03054-y↗
  8. Correlation of intratumoral mast cell quantity with psychosocial distress in patients with pancreatic cancer: the PancStress study. Co-author DOI 10.1038/s41598-024-77010-8↗
  9. Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2021-325564↗
  10. βIII-Tubulin is a Brake on Extrinsic Cell-Death in Pancreatic Cancer Co-author DOI 10.1101/2022.09.29.510034↗
  11. Bioengineered 3D models of human pancreatic cancer recapitulate in vivo tumour biology. Co-author DOI 10.1038/s41467-021-25921-9↗
  12. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition. Co-author DOI 10.1158/0008-5472.can-20-2496↗
  13. Telomerase and Pluripotency Factors Jointly Regulate Stemness in Pancreatic Cancer Stem Cells. Co-author DOI 10.3390/cancers13133145↗
  14. A feedback-loop between telomerase activity and stemness factors regulates PDAC stem cells Co-author DOI 10.1101/2020.11.02.361931↗
  15. Pseudopterosin and O-Methyltylophorinidine Suppress Cell Growth in a 3D Spheroid Co-Culture Model of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/bioengineering7020057↗
  16. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/path.5224↗
  17. Stromal heterogeneity in pancreatic cancer and chronic pancreatitis. Co-author DOI 10.1016/j.pan.2018.05.004↗
  18. Co-clinical Assessment of Tumor Cellularity in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-15-2432↗
  19. Contemporary strategies to improve the outcome in locally advanced pancreatic cancer. Co-author DOI 10.23736/s0026-4733.17.07410-7↗
  20. The role of hypoxia in pancreatic cancer: a potential therapeutic target? Co-author DOI 10.1586/17474124.2016.1117386↗
  21. Activated leukocyte cell adhesion molecule regulates the interaction between pancreatic cancer cells and stellate cells. Co-author DOI 10.3892/mmr.2016.5681↗
  22. Collagen type V promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2014.10.020↗
  23. Kif20a inhibition reduces migration and invasion of pancreatic cancer cells. First author DOI 10.1016/j.jss.2015.03.070↗
  24. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/nm.3952↗
  25. A common genetic variation of melanoma inhibitory activity-2 labels a subtype of pancreatic adenocarcinoma with high endoplasmic reticulum stress levels. Co-author DOI 10.1038/srep08109↗
  26. Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment. Co-author DOI 10.1136/gutjnl-2014-308935↗
  27. Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms. Co-author DOI 10.1158/1078-0432.ccr-14-1399↗
  28. Outcomes of resections for pancreatic adenocarcinoma with suspected venous involvement: a single center experience. Co-author DOI 10.1186/s12893-015-0086-1↗
  29. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience. Co-author DOI 10.1245/s10434-015-4851-2↗
  30. βIII-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancer. Co-author DOI 10.18632/oncotarget.2946↗
  31. Hypoxia-induced endoplasmic reticulum stress characterizes a necrotic phenotype of pancreatic cancer. Co-author DOI 10.18632/oncotarget.5168↗
  32. Strategies to improve the outcome in locally advanced pancreatic cancer. Co-author PMID 25658301↗
  33. The role of inflammation in pancreatic cancer. Co-author DOI 10.1007/978-3-0348-0837-8_6↗
  34. Effect of gemcitabine and retinoic acid loaded PAMAM dendrimer-coated magnetic nanoparticles on pancreatic cancer and stellate cell lines. First author DOI 10.1016/j.biopha.2014.07.003↗
  35. Chloroquine targets pancreatic cancer stem cells via inhibition of CXCR4 and hedgehog signaling. Co-author DOI 10.1158/1535-7163.mct-13-0948↗
  36. Understanding the stroma of pancreatic cancer: co-evolution of the microenvironment with epithelial carcinogenesis. Co-author DOI 10.1002/path.4213↗
  37. The role of pancreatic stellate cells in pancreatic cancer. Co-author DOI 10.1016/j.pan.2013.01.008↗
  38. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Co-author DOI 10.1038/nrgastro.2012.115↗
  39. Syndecan-2 promotes perineural invasion and cooperates with K-ras to induce an invasive pancreatic cancer cell phenotype. Co-author DOI 10.1186/1476-4598-11-19↗
  40. The impact of the activated stroma on pancreatic ductal adenocarcinoma biology and therapy resistance. Co-author DOI 10.2174/156652412799218921↗
  41. How fibrosis influences imaging and surgical decisions in pancreatic cancer. Co-author DOI 10.3389/fphys.2012.00389↗
  42. Glutamate increases pancreatic cancer cell invasion and migration via AMPA receptor activation and Kras-MAPK signaling. Co-author DOI 10.1002/ijc.25898↗
  43. Comparison of diffusion-weighted MR imaging and multidetector-row CT in the detection of liver metastases in patients operated for pancreatic cancer. Co-author DOI 10.1007/s00261-010-9633-5↗
  44. Pigment epithelium-derived factor associates with neuropathy and fibrosis in pancreatic cancer. First author DOI 10.1038/ajg.2010.479↗
  45. From tissue turnover to the cell of origin for pancreatic cancer. Co-author DOI 10.1038/nrgastro.2011.114↗
  46. Tenascin-C enhances pancreatic cancer cell growth and motility and affects cell adhesion through activation of the integrin pathway. Co-author DOI 10.1371/journal.pone.0021684↗

Closest collaborators

The 25 strongest of 135 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jorg H. Kleeff · 27 shared papers, 2011–2026 · strength 1.53
  2. Iréne Esposito · 14 shared papers, 2011–2026 · strength 0.87
  3. David Goldstein · 6 shared papers, 2015–2026 · strength 0.83
  4. Joshua A. McCarroll · 6 shared papers, 2015–2026 · strength 0.83
  5. Amber L. Johns · 6 shared papers, 2015–2026 · strength 0.83
  6. Phoebe A. Phillips · 6 shared papers, 2015–2026 · strength 0.83
  7. George Sharbeen · 6 shared papers, 2015–2026 · strength 0.83
  8. Koroush Shahsavar Haghighi · 5 shared papers, 2021–2026 · strength 0.79
  9. Anthony James Gill · 5 shared papers, 2021–2026 · strength 0.79
  10. John Kokkinos · 5 shared papers, 2021–2026 · strength 0.79
  11. Helmut Friess · 8 shared papers, 2011–2026 · strength 0.70
  12. Val Gebski · 4 shared papers, 2021–2026 · strength 0.59
  13. Jennifer P. Morton · 4 shared papers, 2021–2026 · strength 0.59
  14. Marina Pajic · 4 shared papers, 2021–2026 · strength 0.58
  15. Christoph W. Michalski · 14 shared papers, 2011–2015 · strength 0.57
  16. Guralp Onur Ceyhan · 4 shared papers, 2011–2026 · strength 0.55
  17. Rickmer Braren · 6 shared papers, 2015–2026 · strength 0.52
  18. İhsan Ekin Demir · 3 shared papers, 2011–2026 · strength 0.50
  19. Simone Hausmann · 6 shared papers, 2012–2026 · strength 0.50
  20. Ilaria Pergolini · 2 shared papers, 2024–2026 · strength 0.48
  21. Jens Thomas Siveke · 5 shared papers, 2015–2026 · strength 0.47
  22. Bo Kong · 11 shared papers, 2011–2015 · strength 0.45
  23. Marija Trajkovic‐Arsic · 4 shared papers, 2015–2026 · strength 0.43
  24. Irina Heid · 4 shared papers, 2015–2026 · strength 0.43
  25. Roland Michael Schmid · 4 shared papers, 2015–2026 · strength 0.43

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.